These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9487438)

  • 1. Review of five paradigm papers on economic, biomedical, community, sociocultural and political perspectives in improving use of medicines.
    Anokbonggo WW
    East Afr Med J; 1997 Sep; 74(9):591-5. PubMed ID: 9487438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric therapeutics and medicine administration in resource-poor settings: a review of barriers and an agenda for interdisciplinary approaches to improving outcomes.
    Craig SR; Adams LV; Spielberg SP; Campbell B
    Soc Sci Med; 2009 Dec; 69(11):1681-90. PubMed ID: 19796859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
    Forsythe SS
    AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug therapy, testimony to our world and our time].
    Joly P
    Bull Acad Natl Med; 1991 Jan; 175(1):67-76; discussion 76-8. PubMed ID: 1863859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment in Catalonia: an overview of past and future perspectives.
    de Solà-Morales O; Granados A
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():88-93. PubMed ID: 19519981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technological and social innovation: a unifying new paradigm for global health.
    Gardner CA; Acharya T; Yach D
    Health Aff (Millwood); 2007; 26(4):1052-61. PubMed ID: 17630448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing and using quality measures for children's health care: perspectives on the state of the practice.
    Shaller D
    Pediatrics; 2004 Jan; 113(1 Pt 2):217-27. PubMed ID: 14702504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-governmental organizations in international health: past successes, future challenges.
    Gellert GA
    Int J Health Plann Manage; 1996; 11(1):19-31. PubMed ID: 10157062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health seeking behaviour and health service utilization in Pakistan: challenging the policy makers.
    Shaikh BT; Hatcher J
    J Public Health (Oxf); 2005 Mar; 27(1):49-54. PubMed ID: 15590705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confidence in vaccines in developing countries: social, cultural, economic and political influences.
    Mulholland K; Korczak V; Tangcharoensathien V
    J Epidemiol Community Health; 2010 Jul; 64(7):563-4. PubMed ID: 20466706
    [No Abstract]   [Full Text] [Related]  

  • 16. Socio-economic implication of multi-drug resistant malaria in the community; how prepared is Nigeria for this emerging problem?
    Chukwuani CM
    West Afr J Med; 1999; 18(4):303-6. PubMed ID: 10734797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economic value of individualizing drug therapy.
    Navarro RP
    Manag Care Interface; 1997 Oct; 10(10):96-8. PubMed ID: 10174423
    [No Abstract]   [Full Text] [Related]  

  • 18. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rich countries and poor countries revisited.
    Gallagher CF
    Rep Am Univ Field Staff; 1979; 34():1-12. PubMed ID: 12179858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis and innovation.
    Jena AB; Philipson TJ
    J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.